CBChristian Barrère

Christian Barrère

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christian Barrère has a total of 120 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A novel therapeutic peptide targeting myocardial reperfusion injury

    by Prisca Boisguérin, Aurélie Covinhes, Laura Gallot, Christian Barrère, Anne Vincent, Muriel Busson, Christophe Piot, Joël Nargeot, Bernard Lebleu, Stéphanie Barrère-Lemaire

    Regulated cell death is a main contributor of myocardial ischaemia-reperfusion (IR) injury during acute myocardial infarction. In this context, targeting apoptosis could be a potent therapeutical strategy. In a previous study, we showed that DAXX (death-associated protein) was essential for transducing the FAS-dependent apoptotic signal during IR injury. The present study aims at evaluating the cardioprotective effects of a synthetic peptide inhibiting FAS:DAXX interaction. An interfering peptide was engineered and then coupled to the Tat cell penetrating peptide (Tat-DAXXp). Its internalization and anti-apoptotic properties were demonstrated in primary cardiomyocytes. Importantly, an intravenous bolus injection of Tat-DAXXp (1 mg/kg) 5 min before reperfusion in a murine myocardial IR model decreased infarct size by 48% after 24 h of reperfusion. In addition, Tat-DAXXp was still efficient after a 30-min delayed administration, and was completely degraded and eliminated within 24 h thereby reducing risks of potential side effects. Importantly, Tat-DAXXp reduced mouse early post-infarction mortality by 67%. Mechanistically, cardioprotection was supported by both anti-apoptotic and pro-survival effects, and an improvement of myocardial functional recovery as evidenced in ex vivo experiments. Our study demonstrates that a single dose of Tat-DAXXp injected intravenously at the onset of reperfusion leads to a strong cardioprotection in vivo by inhibiting IR injury validating Tat-DAXXp as a promising candidate for therapeutic application.


  • Open Access

    Acute and long-term cardioprotective effects of the Traditional Chinese Medicine MLC901 against myocardial ischemia-reperfusion injury in mice

    by Anne Vincent, Aurélie Covinhes, Christian Barrère, Laura Gallot, Soulit Thoumala, Christophe Piot, Catherine Heurteaux, Michel Lazdunski, Joël Nargeot, Stéphanie Barrère-Lemaire

    MLC901, a traditional Chinese medicine containing a cocktail of active molecules, both reduces cerebral infarction and improves recovery in patients with ischemic stroke. The aim of this study was to evaluate the acute and long-term benefits of MLC901 in ischemic and reperfused mouse hearts. Ex vivo, under physiological conditions, MLC901 did not show any modification in heart rate and contraction amplitude. However, upon an ischemic insult, MLC901 administration during reperfusion, improved coronary flow in perfused hearts. In vivo, MLC901 (4 µg/kg) intravenous injection 5 minutes before reperfusion provided a decrease in both infarct size (49.8%) and apoptosis (49.9%) after 1 hour of reperfusion. Akt and ERK1/2 survival pathways were significantly activated in the myocardium of those mice. In the 4-month clinical follow-up upon an additional continuous per os administration, MLC901 treatment decreased cardiac injury as revealed by a 45%-decrease in cTnI plasmatic concentrations and an improved cardiac performance assessed by echocardiography. A histological analysis revealed a 64%-decreased residual scar fibrosis and a 44%-increased vascular density in the infarct region. This paper demonstrates that MLC901 treatment was able to provide acute and long-term cardioprotective effects in a murine model of myocardial ischemia-reperfusion injury in vivo.


  • Cardiac mGluR1 metabotropic receptors in cardioprotection

    by Anne Vincent, Catherine Sportouch, Aurélie Covinhes, Christian Barrère, Laura Gallot, Viviana Delgado-Betancourt, Benoît Lattuca, Kamila Solecki, Prisca Boisguérin, Christophe Piot, et al.

    In a previous study using a genome-wide microarray strategy, we identified metabotropic glutamate receptor 1 (mGluR1) as a putative cardioprotective candidate in ischaemic postconditioning (PostC). In the present study, we investigated the role of cardiac mGluR1 receptors during cardioprotection against myocardial ischaemia-reperfusion injury in the mouse myocardium. mGluR1 activation by glutamate administered 5 min before reperfusion in C57Bl/6 mice subjected to a myocardial ischaemia protocol strongly decreased both infarct size and DNA fragmentation measured at 24 h reperfusion. This cardioprotective effect was mimicked by the mGluR1 agonist, DHPG (10 μM), and abolished when glutamate was coinjected with the mGluR1 antagonist YM298198 (100 nM). Wortmannin (100 nM), an inhibitor of PI3-kinase, was able to prevent glutamate-induced cardioprotection. A glutamate bolus at the onset of reperfusion failed to protect the heart of mGluR1 knockout mice subjected to a myocardial ischaemia-reperfusion protocol, although PostC still protected the mGluR1 KO mice. Glutamate-treatment improved post-infarction functional recovery as evidenced by an echocardiographic study performed 15 days after treatment and by a histological evaluation of fibrosis 21 days post-treatment. Interestingly, restoration of functional mGluR1s by a PostC stimulus was evidenced at the transcriptional level. Since mGluR1s were localized at the surface membrane of cardiomyocytes, they might contribute to the cardioprotective effect of ischaemic PostC as other Gq-coupled receptors. This study provides the first demonstration that mGluR1 activation at the onset of reperfusion induces cardioprotection and might represent a putative strategy to prevent ischaemia-reperfusion injury.


  • Open Access

    L-type Cav1.3 channels regulate ryanodine receptor-dependent Ca2+release during sino-atrial node pacemaker activity

    by Angelo Giovanni Torrente, Pietro Mesirca, Patricia Neco, Riccardo Rizzetto, Stefan Dubel, Christian Barrere, Martina Sinegger-Brauns, Joerg Striessnig, Sylvain Richard, Joël Nargeot, et al.

    Sino-atrial node (SAN) automaticity is an essential mechanism of heart rate generation that is still not completely understood. Recent studies highlighted the importance of intracellular Ca2+ ([Ca2+]i) dynamics during SAN pacemaker activity. Nevertheless, the functional role of voltage-dependent L-type Ca2+ channels in controlling SAN [Ca2+]i release is largely unexplored. Since Cav1.3 is the predominant L-type Ca2+ channel isoform in SAN cells, we studied [Ca2+]i dynamics in isolated cells and ex vivo SAN preparations explanted from wild-type (WT) and Cav1.3 knockout (KO) mice (Cav1.3−/−). We found that Cav1.3 deficiency strongly impaired [Ca2+]i dynamics, reducing the frequency of local [Ca2+]i release events and preventing their synchronization. This impairment inhibited the generation of Ca2+ transients and delayed spontaneous activity. We also used action potentials recorded in WT SAN cells as voltage-clamp commands for Cav1.3−/− cells. Although these experiments showed abolished Ca2+ entry through L-type Ca2+ channels in the diastolic depolarization range of KO SAN cells, their sarcoplasmic reticulum Ca2+ load remained normal. β-Adrenergic stimulation enhanced pacemaking of both genotypes, though, Cav1.3−/− SAN cells remained slower than WT. Conversely, we rescued pacemaker activity in Cav1.3−/− SAN cells and intact tissues through caffeine-mediated stimulation of Ca2+-induced Ca2+ release. Cav1.3 channels play a critical role in the regulation of [Ca2+]i dynamics, providing an unanticipated mechanism for triggering local [Ca2+]i releases and thereby controlling pacemaker activity. Our study also provides an additional pathophysiological mechanism for congenital SAN dysfunction and heart block linked to Cav1.3 loss of function in humans.


  • Open Access

    TAFA4, a Chemokine-like Protein, Modulates Injury-Induced Mechanical and Chemical Pain Hypersensitivity in Mice

    by Marie-Claire Delfini, Annabelle Mantilleri, Stéphane Gaillard, Jizhe Hao, Ana Reynders, Pascale Malapert, Serge Alonso, Amaury François, Christian Barrere, Rebecca Seal, et al.


  • State-dependent properties of a new T-type calcium channel blocker enhance CaV3.2 selectivity and support analgesic effects

    by Amaury Francois, Nicolas Kerckhove, Mathieu Meleine, Abdelkrim Alloui, Christian Barrere, Agathe Gelot, Victor N. Uebele, John J. Renger, Alain Eschalier, Denis Ardid, et al.

    T-type calcium channels encoded by the Ca(V)3.2 isoform are expressed in nociceptive primary afferent neurons where they contribute to hyperalgesia and thus are considered as a potential therapeutic target to treat pathological pain. Here we report that the small organic state-dependent T-type channel antagonist TTA-A2 efficiently inhibits recombinant and native Ca(V)3.2 currents. Although TTA-A2 is a pan Ca(V)3 blocker, it demonstrates a higher potency for Ca(V)3.2 compared to Ca(V)3.1. TTA-A2 selectivity for T-type currents was demonstrated in sensory neurons where it lowered cell excitability uniquely on neurons expressing T-type channels. In vivo pharmacology in Ca(V)3.2 knockout and wild type mice reveal that TTA-A2-mediated antinociception critically depends on Ca(V)3.2 expression. The pathophysiology of irritable bowel syndrome (IBS) was recently demonstrated to involve Ca(V)3.2 in a rat model of this disease. Oral administration of TTA-A2 produced a dose-dependent reduction of hypersensitivity in an IBS model, demonstrating its therapeutic potential for the treatment of pathological pain. Overall, our results suggest that the high potency of TTA-A2 in the depolarized state strengthen its analgesic efficacy and selectivity toward pathological pain syndromes. This characteristic would be beneficial for the development of analgesics targeting T-type channels, in particular for the treatment of pain associated with IBS.


  • Open Access

    AKAP79 modulation of L-type channels involves disruption of intramolecular interactions in the CaV1.2 subunit

    by Christophe Altier, Stefan J. Dubel, Christian Barrere, Scott E. Jarvis, Stephanie C. Stotz, John D. Scott, Joel Nargeot, Gerald W. Zamponi, Emmanuel Bourinet

    L-type voltage gated calcium channels (VGCCs) interact with a variety of proteins that modulate both their function and localization. A-Kinase Anchoring Proteins (AKAPs) facilitate L-type calcium c...


  • Open Access

    Down-regulation of the transcription factor ZAC1 upon pre- and postconditioning protects against I/R injury in the mouse myocardium

    by Anne Vincent, Gérald Gahide, Catherine Sportouch-Dukhan, Aurélie Covinhes, Alicia Franck-Miclo, François Roubille, Christian Barrère, Jérôme Adda, Christelle Dantec, Christelle Redt-Clouet, et al.

    Myocardial infarction leads to heart failure and death. Ischaemic preconditioning (PreC) and postconditioning (PostC) reduce infarct size in animal models and human. Zac1 was identified as the only gene related to apoptosis and jointly down-regulated upon PreC and PostC. The aim of our study was to investigate the role of Zac1 down-regulation during ischaemia-reperfusion (I/R) in vivo. C57BL/6 mice were submitted to myocardial I/R injury, PreC, or PostC protocols. QPCR and immunochemistry showed that Zac1 expression was down-regulated both at the transcriptional and the protein levels upon PreC and PostC. Zac1−/− Knockout mice (n = 7) developed smaller infarcts (54%) than Zac1+/+ littermates (n = 8) and decreased apoptosis (61.7%) in the ischaemic part of the left ventricle during I/R (Zac1−/−, n = 6 vs. Zac1+/+, n = 7; P = 0.0012). Mutants showed under control conditions a decrease of 53.9% in mRNA of Daxx, a pro-apoptotic protein playing a key role in I/R injuries (4.81 ± 0.77, n = 4 Zac1−/− mice vs. 10.44 ± 3.5, n = 7 Zac1+/+ mice; P = 0.0121). Our study shows for the first time that Zac1 is down-regulated both at the transcriptional and protein levels upon PreC and PostC in wild-type mice. Moreover, inactivation of Zac1 in vivo is associated with a decreased amount of Daxx transcripts and, upon I/R injury, decreased infarct size and apoptosis. Altogether, our results show that Zac1 down-regulation plays a key role during cardioprotection against I/R injury and support the concept that cardioprotection regulates a network of interacting pro-apoptotic genes including Zac1 and Daxx.


  • T-type calcium channels contribute to colonic hypersensitivity in a rat model of irritable bowel syndrome

    by Fabrice Marger, Agathe Gelot, Abdelkrim Alloui, Julien Matricon, Juan F. Sanguesa Ferrer, Christian Barrère, Anne Pizzoccaro, Emilie Muller, Joël Nargeot, Terrance P. Snutch, et al.

    The symptoms of irritable bowel syndrome (IBS) include significant abdominal pain and bloating. Current treatments are empirical and often poorly efficacious, and there is a need for the development of new and efficient analgesics aimed at IBS patients. T-type calcium channels have previously been validated as a potential target to treat certain neuropathic pain pathologies. Here we report that T-type calcium channels encoded by the CaV3.2 isoform are expressed in colonic nociceptive primary afferent neurons and that they contribute to the exaggerated pain perception in a butyrate-mediated rodent model of IBS. Both the selective genetic inhibition of CaV3.2 channels and pharmacological blockade with calcium channel antagonists attenuates IBS-like painful symptoms. Mechanistically, butyrate acts to promote the increased insertion of CaV3.2 channels into primary sensory neuron membranes, likely via a posttranslational effect. The butyrate-mediated regulation can be recapitulated with recombinant CaV3.2 channels expressed in HEK cells and may provide a convenient in vitro screening system for the identification of T-type channel blockers relevant to visceral pain. These results implicate T-type calcium channels in the pathophysiology of chronic visceral pain and suggest CaV3.2 as a promising target for the development of efficient analgesics for the visceral discomfort and pain associated with IBS.